Summit Veterinary Referral Center

Specialty hospital / research center

2 current cancer treatment or research opportunities

About Summit Veterinary Referral Center

Summit Veterinary Referral Center is the participating hospital named in the current study listing below. The hospital is part of the Ethos Veterinary Health network, while Ethos Discovery coordinates the research program. Screening, enrollment and required visits are handled by the participating hospital; owners should confirm that the location is still enrolling before making travel plans.

Summit Veterinary Referral Center official website →

Who the current listings are forDogs
Cancer types currently listedHemangiosarcoma, Oral Melanoma
Where visits take placeSummit Veterinary Referral Center, 2505 S 80th St, Tacoma, WA 98409

Current options at Summit Veterinary Referral Center

Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.

Gilvetmab treatment study for canine malignant melanoma

Ethos Veterinary Health · USA

Now enrolling patients

What is being offered: Safety and efficacy study of gilvetmab in dogs with malignant melanoma; age ≥1 year.

Who may qualify: Confirmed cancer diagnosis required; Min weight lb: 6.6; Active tumor required; Min age years: 1

Costs / coverage: 🟢 Fully funded. All study-related visits are covered at no cost to the pet owner.

Contact: Contact participating Ethos hospital through official study page.

Location

  • Summit Veterinary Referral Center, 2505 S 80th St, Tacoma, WA 98409

Official study / enrollment information →

Ethos-PUSH precision-medicine umbrella study for splenic hemangiosarcoma

Ethos Discovery / multicenter specialty hospitals · USA

Open / currently enrolling

What is being offered: Phase 1 splenectomy/hemoabdomen study; dogs confirmed with non-metastatic splenic HSA can continue to fully funded active-treatment Phase 2, with treatment assigned among doxorubicin, doxorubicin+rapamycin, doxorubicin+sorafenib, or oral paclitaxel regimens.

Who may qualify: No metastasis; Active tumor required; Splenic primary; Planned surgery; Pre splenectomy; Min weight kg exclusive: 5; Max weight kg exclusive: 45

Costs / coverage: 🟡 Partially funded overall. Phase 1 provides $1,000 toward splenectomy; owners remain responsible for other initial surgical/screening costs. Dogs subsequently confirmed with splenic HSA and no metastases can enter fully funded Phase 2 (> $10,000 value). Sponsor states up to $3,000 for study-related side effects.

Contact: Ethos Discovery enrollment form / participating hospital; CASE: 303-545-2273

Location

  • Summit Veterinary Referral Center, 2505 S 80th St, Tacoma, WA 98409

Official study / enrollment information →

Before you contact the center

A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.

Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.

Check all options for your pet →

Free to use. No registration or paid report.